French, Jena D.
Haugen, Bryan R.
Article History
First Online: 24 November 2017
Competing interests
: The authors have received research support from Merck and Eisai for a phase II clinical trial investigating lenvatinib and pembrolizumab in treating patients with advanced differentiated thyroid cancer.